Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept

Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept

The investigators intend to show that DDAVP improves platelet activity from baseline to 60 minutes after treatment start.

Inclusion Criteria:

• Spontaneous intracerebral hemorrhage as documented by head CT scan
• Documented regular aspirin use or VerifyNow-ASA result of ≤ 550 aspirin reaction units (ARU), indicating anti-platelet medication

Exclusion Criteria:

• International normalized ratio (INR) of ≥ 1.7 from coagulopathy or warfarin use
• History of von Willebrand disease
• Pregnancy
• Known hypersensitivity to DDAVP or desmopressin
• Active cardiovascular disease or unstable angina
• Hyponatremia or history of hyponatremia
• Current or historical deep venous thrombosis or pulmonary embolism